SLNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Soleno Therapeutics Inc (SLNO) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown strong revenue growth and positive analyst sentiment, the technical indicators are bearish, insider selling is significant, and there are no strong proprietary trading signals. The current price trend and lack of clear positive momentum suggest holding off on investment for now.
The technical indicators for SLNO are bearish. The MACD is positive but contracting, RSI is neutral at 38.738, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading close to its pivot level of 37.739, with resistance at 41.173 and support at 34.304. This suggests limited upward momentum in the short term.
Strong Q4 revenue growth of $91.7 million, a 40% increase from Q
Positive analyst sentiment with raised price targets and buy ratings.
Appointment of a new CFO, which could bring fresh strategic direction.
Significant insider selling, with a 1314.42% increase in the last month.
Bearish technical indicators and lack of strong upward momentum.
No recent congress trading data or strong proprietary trading signals.
In Q4 2025, Soleno Therapeutics reported revenue of $91.7 million, up 40% QoQ, but net income dropped significantly by -176.71% YoY. EPS also declined by -156.69% YoY to $0.72. Gross margin remained strong at 99.06%. While revenue growth is impressive, profitability metrics have deteriorated.
Analysts maintain a positive outlook on SLNO with multiple buy ratings and raised price targets. TD Cowen lowered its target to $85 but reaffirmed a strong commercial trajectory. Wells Fargo raised its target to $114, citing strong revenue performance. H.C. Wainwright increased its target to $120, highlighting consistent sales outperformance.
